Skip to main content
SpringerLink
Log in

Zinc l-carnosine in gastric ulcers: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Oral zinc l-carnosine (Gastrozin®) 75 mg twice daily is an effective gastric mucoprotective option for the treatment and prevention of gastric ulcers. The two components of the chelated compound (i.e. zinc and l-carnosine in a 1:1 ratio) provide beneficial anti-inflammatory, antioxidant and other effects that work together to support the natural mucoprotective mechanisms of the gastrointestinal tract. Zinc l-carnosine 75 mg twice daily has well established efficacy in the treatment of gastric ulcers, and is at least as effective as other mucoprotectants in this indication. It consistently provides rapid healing of gastric ulcers regardless of their underlying cause, such as gastritis, Helicobacter pylori infection and endoscopic submucosal dissection (ESD), or concurrent pharmacological treatment (e.g. H. pylori eradication or proton pump inhibitor therapy).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Choi HS, Kim ES, Keum B, et al. l-carnosine and zinc in gastric protection. In: Preedy VR, editor. Food and Nutritional Components in Focus. Cambridge: Royal Society of Chemistry; 2015. p. 548–65.

    Google Scholar 

  2. Myran L, Zarbock SD. Management of Helicobacter pylori infection. US Pharm. 2019;43(4):27–32.

    Google Scholar 

  3. Gastrozin (75 mg zinc l-carnosine tablet): package leaflet. Dubai: Synergy Pharma. 2019.

  4. Hudson T. Nutrient profile: zinc-carnosine: a combination of zinc and l-carnosine improves gastric ulcers. Natural Med J. 2013;5:11.

    Google Scholar 

  5. Matsukura T, Tanaka H. Applicability of zinc complex of l-carnosine for medical use. Biochem (Mosc). 2000;65(7):817–23.

    CAS  Google Scholar 

  6. Soderberg TA, Sunzel B, Holm S, et al. Antibacterial effect of zinc oxide in vitro. Scan J Plast Reconstr Sug Hand Surg. 1990;24(3):93–107.

    Google Scholar 

  7. Prasad A. Zinc: an overview. Nutrition. 1995;11(1 Suppl):93–9.

    CAS  PubMed  Google Scholar 

  8. Opoka W, Adamek D, Plonka M, et al. Importance of luminal and mucosal zinc in the mechanism of experimental gastric ulcer healing. J Physiol Pharmacol. 2010;61(5):581–91.

    CAS  PubMed  Google Scholar 

  9. Korolkiewicz R, Fujita A, Seto K, et al. Polaprezinc exerts a salutary effect on impaired healing of acute gastric lesions in diabetic rats. Dig Dis Sci. 2000;45(6):1200–9.

    Article  CAS  PubMed  Google Scholar 

  10. Furata S, Toyama S, Miwa M, et al. Residence time of polaprezinc (zinc l-carnosine complex in the rat stomach and adhesiveness to ulcerous sites. Jpn J Pharmacol. 1995;67(4):271–8.

    Article  Google Scholar 

  11. Gaby AR. Therapeutic agents part 2B: minerals. Nutritional medicine. 2nd ed. Concord (NH): Nutritional Medicine. 2017.

  12. Ito M, Tanaka T, Suzuki Y. Effect of N-(3-aminopropionyl)-l-histidinato zinc (Z-103) on healing and hydrocortisone-induced relapse of acetic acid ulcers in rats with limited food intake-time. Jpn J Pharmacol. 1990;52(4):513–21.

    Article  CAS  PubMed  Google Scholar 

  13. Baan M, Sherding RG, Johnson SE. Effects of zinc-l-carnosine and vitamin E on aspirin-induced gastroduodenal injury in dogs. J Vet Intern Med. 2011;25(1):39–46.

    Article  CAS  PubMed  Google Scholar 

  14. Naito Y, Yoshikawa T, Yagi N, et al. Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-α expression in rats with aspirin-induced gastric mucosal injury. Dig Dis Sci. 2001;46(4):845–51.

    Article  CAS  PubMed  Google Scholar 

  15. Choi HS, Lim J, Chun HJ, et al. The effect of polaprezinc on gastric mucosal protection in rats with ethanol-induced gastric mucosal damage: comparison study with rebamipide. Life Sci. 2013;9(2–3):69–77.

    Article  CAS  Google Scholar 

  16. Ko JK, Leung CC. Ginger extract and polaprezinc exert gastroprotective actions by anti-oxidant and growth factor modulating effects in rats. J Gastroenterol Hepatol. 2010;25(12):1861–8.

    Article  PubMed  Google Scholar 

  17. Shimada T, Watanabe N, Ohtuka Y, et al. Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-κB activiation and interleukin-8 expression in gastric epithelial cells. J Pharmacol Exp Ther. 1999;291(1):345–52.

    CAS  PubMed  Google Scholar 

  18. Handa O, Yoshida N, Tanaka Y, et al. Inhibitory effect of polaprezinc on the inflammatory response to Helicobacter pylori. Can J Gastroenterol. 2002;16(11):785–9.

    Article  PubMed  Google Scholar 

  19. Ishihara R, Iishi H, Sakai N, et al. Polaprezinc attenuates Helicobacter pylori-associated gastritis in Mongolian gerbils. Helicobacter. 2002;7(6):384–9.

    Article  CAS  PubMed  Google Scholar 

  20. Ito M, Shii D, Segami T, et al. Preventive actions of N-(3-aminopropionyl)-l-histidinato zinc (Z-103) through increases in the activities of oxygen-derived free radical scavenging enzymes in the gastric mucosa on ethanol-induced gastric mucosal damage in rats. Jpn J Pharmacol. 1992;59(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  21. Yoshikawa T, Naito Y, Tanigawa T, et al. The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l-histidinato zinc. Biochim Biophys Acta. 1991;1115(5):15–22.

    Article  CAS  PubMed  Google Scholar 

  22. Ueda K, Ueyama T, Oka M, et al. Polaprezinc (zinc l-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1: a new mechanism of gastric mucosal protection. J Pharmacol Sci. 2009;110(3):285–94.

    Article  CAS  PubMed  Google Scholar 

  23. Omatsu T, Naito Y, Handa O, et al. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol. 2010;45(7):692–702.

    Article  CAS  PubMed  Google Scholar 

  24. Fujii Y, Matsura T, Kai M, et al. Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. Jpn J Pharmacol. 2000;84(1):63–70.

    Article  CAS  Google Scholar 

  25. Yoshikawa T, Yamaguchi T, Yoshida N, et al. Effect of Z-103 on TNB-induced colitis in rats. Digestion. 1997;58(5):464–8.

    Article  CAS  PubMed  Google Scholar 

  26. Hiraishi H, Sasai T, Oinuma T, et al. Polaprezinc protects gastric mucosal cells from noxious agents through antioxidant properties in vitro. Aliment Pharmacol Ther. 1999;13(2):261–9.

    Article  CAS  PubMed  Google Scholar 

  27. Yoshikawa T, Naito Y, Tanigawa T, et al. Effect of zinc-carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric mucosal injury induced by ischemia-reperfusion in rats. Free Radic Res Commun. 1991;14(4):289–96.

    Article  CAS  PubMed  Google Scholar 

  28. Watanabe S, Wang XE, Hirose M, et al. Insulin-like growth factor I plays a role in gastric wound healing: evidence using a zinc derivative, polaprezinc, and an in vitro rabbit wound repair model. Aliment Pharmacol Ther. 1998;12(11):1131–8.

    Article  CAS  PubMed  Google Scholar 

  29. Odashima M, Otaka M, Jin M, et al. Induction of a 72-kDa heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc l-carnosine. Dig Dis Sci. 2001;47(12):2799–804.

    Article  Google Scholar 

  30. Wada I, Otaka M, Jin M, et al. Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats: correlation of HSP72 expression with mucosal protection. Biochem Biophys Res Commun. 2006;349(2):611–8.

    Article  CAS  PubMed  Google Scholar 

  31. Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168–75.

    Article  CAS  PubMed  Google Scholar 

  32. Watari I, Oka S, Tanaka S, et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol. 2013;13:108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mitani T, Shirasaka D, Miyachi H. Can polaprezinc be attributed to reduce the risk of gastric carcinogenesis in Helicobacter pylori-positive young people? [abstract no. 136]. Am J Gastroenterol. 2007;102(Suppl 2):S167.

    Article  Google Scholar 

  34. Murakami K, Sato R, Okimoto T, et al. Influence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol. 2003;38(10):937–41.

    Article  CAS  PubMed  Google Scholar 

  35. Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 in the treatment of gastric ulcers: a multicenter double-blind dose finding study [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):181–97.

    Google Scholar 

  36. Miyoshi A, Namiki M, Iwasaki A, et al. Clinical evaluation of Z-103 in the treatment of gastritis: a multicenter double-blind dose finding study [in Japanese]. Jpn Pharmacol Ther. 1997;25(5):1403–42.

    Google Scholar 

  37. Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 in the treatment of gastritis: an open-label dose finding study [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):245–54.

    Google Scholar 

  38. Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 (polaprezinc) on gastric ulcer: a multicenter double-blind comparative study with cetraxate hydrochloride [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):199–223.

    Google Scholar 

  39. Nakajima M. Clinical evaluation of Z-103 on gastritis: a double-blind controlled study using sucralfate as a comparator. Pharmacol Ther. 1997;25(4):325–66.

    Google Scholar 

  40. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999;13(4):483–7.

    Article  CAS  PubMed  Google Scholar 

  41. Tan B, Luo HQ, Xu H, et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: a prospective, multicenter, randomized clinical trial. PLoS One. 2017;12(4):e0175625.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Sugimoto N, Yoshikawa T, Naito Y, et al. Triple therapy of lansoprazole + amoxicillin + metronidazole versus triple plus mucosal protective drug polaprezinc therapy for cure of Helicobacter pylori (HP) in gastric ulcer patients [abstract]. Gastroenterology. 1997;112:A300.

    Google Scholar 

  43. Baniya R, Upadhaya S, Chughtai K, et al. Is polaprezinc a missing link in Helicobacter pylori eradication therapy? A meta-analysis of randomized controlled trials of triple therapy with polaprezinc [abstract no. 1249]. Am J Gastroenterol. 2017;112(Suppl 1):S680-S1.

    Google Scholar 

  44. Isomoto H, Furusu H, Ohnita K, et al. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. World J Gastroenterol. 2005;11(11):1629–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Inaba T, Ishikawa S, Toyokawa T, et al. Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc. Hepatogastroenterology. 2010;57(99–100):678–84.

    CAS  PubMed  Google Scholar 

  46. Jung DH, Park JC, Lee YC, et al. Comparison of the efficacy of polaprezinc plus proton pump inhibitor and rebamipide plus proton pump inhibitor treatment for ESD-induced gastric ulcers: a randomized prospective controlled study [abstract no. Mo1107]. Gastrointest Endosc. 2017;85(5 Suppl 1):AB431.

    Article  Google Scholar 

  47. Dajani A, Abuhammour A. A modified sequential regimen of Helicobacter pylori treatment enforced by Bacillus clausii and zinc carnosine complex yields high eradication rates [abstract no. P-0040]. J Gastroenterol Hepatol. 2017;32(Suppl 3):61–2.

    Google Scholar 

  48. Dajani AI, Nounou MA, Fayadh MH, et al. Zinc carnosine complex improves the response to triple therapy of Helicobacter pylori eradication [abstract no. P-0279]. J Gastroenterol Hepatol. 2017;32(Suppl 3):72.

    Google Scholar 

  49. Ardesia M, Fries W, Palombieri A, et al. Influence of polaprezinc on efficacy of Helicobacter pylori eradication therapy in Italian population [abstract no. P.02.14]. Dig Liver Dis. 2017;49(Suppl 2):e143.

    Article  Google Scholar 

  50. Ishihama H, Sayo S, Yokoyama T, et al. Preventive and therapeutic effects of polaprezinc suspension on oral mucosal injury [abstract no. P1-032]. Ann Oncol. 2013;24(Suppl 9):ix66.

    Article  Google Scholar 

  51. Watanabe T, Ishihara M, Matsuura K, et al. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer. 2010;127(8):1984–90.

    Article  CAS  PubMed  Google Scholar 

  52. Yanase K, Funaguchi N, Iihara H, et al. Prevention of radiation esophagitis by polaprezinc (zinc l-carnosine) in patients with non-small cell lung cancer who received chemoradiotherapy. Int J Clin Exp Med. 2015;8(9):16215–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Sakae K, Agata T, Kamide R, et al. Effects of l-carnosine and its zinc complex (polaprezinc) on pressure ulcer healing. Nutr Clin Pract. 2013;28(5):609–16.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: H. Parthasarathy, Department of Cardiology, Apollo Hospitals, Chennai, India, Y. Prashar, Department of Pharmacology, Rayat Institute of Pharmacy, Railmajra, India; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; A.K. Srivastava, Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India. During the peer review process, Synergy Pharma, the marketing-authorization holder of the Gastrozin® formulation of zinc l-carnosine, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

KA. Lyseng-Williamson is an employee of Adis International Ltd./Springer Nature and the Editor of Drugs & Therapy Perspectives; she has no other conflicts of interest to declare. The Editor of D&TP was not involved in any publishing decisions for the manuscript.

Additional information

Additional information

for this Adis Drug Q&A can be found at https://doi.org/10.6084/m9.figshare.9209471.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Zinc l-carnosine in gastric ulcers: a profile of its use. Drugs Ther Perspect 35, 463–469 (2019). https://doi.org/10.1007/s40267-019-00667-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-019-00667-z

Search

Navigation